Stocks · News reference
HCW Biologics shares are trading lower. The company announced it has requested Type B pre-IND meeting with the FDA to discuss development and regulatory strategy for its investigational tetravalent T-cell engager, HCW11-018b.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HCW Biologics, Partners Identify TGF-β Trap, IL-15 Fusion As Novel Moiety With Potential Applications Against Diseased Cell, Viral Infections
HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 70.3% to $9.28 during Tuesday's after-market session. The market value of their outstanding shares is at $3.2 million. The company's, Q2 earnings came
HCW Biologics Restates Q1 2026 EPS $1.39, Sales $6.543M Up From $5.065K YoY